Ayurcann Holdings Corp. (AYUR) AI Stock Analysis

• Market Cap: C$4.87M
• Dividend Yield: N/A
• Average Volume (3M): 68.91K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.59
• Revenue Growth: 27.80%
• EPS Growth: 31.16%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 44
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 194,703,860
• 10 Day Avg. Volume: 35,000
• 30 Day Avg. Volume: 68,911
• PEG Ratio: -0.07
• Price to Book (P/B): 29.25
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: C$0.00 ▼(-100.00%Downside)

The overall score is primarily influenced by significant financial challenges and valuation concerns, with some positive impact from the company's recent market expansion and strong revenue growth. Technical analysis provides mixed signals, reflecting potential undervaluation but also market volatility concerns.

Ayurcann Holdings Corp. Business Overview & Revenue Model

Company Description

Ayurcann Holdings Corp. (AYUR) is a Canadian company operating in the cannabis sector. The company specializes in the extraction and refinement of cannabis and hemp for the adult-use and medical markets. Its core offerings include cannabis-derived products such as oils, tinctures, and topicals, as well as providing extraction services to licensed cannabis producers.

How the Company Makes Money

Ayurcann Holdings Corp. generates revenue primarily through the sale of cannabis-derived products and by offering extraction services to other licensed cannabis producers. The company leverages its advanced extraction facilities to produce high-quality cannabis oils and related products for both wholesale and retail markets. Additionally, Ayurcann partners with other cannabis companies to support their production needs, thereby securing consistent income streams from service contracts and sales agreements. These partnerships and a focus on cost-efficient operations contribute significantly to the company's earnings.

Ayurcann Holdings Corp. Financial Statement Overview

Summary

Despite strong revenue growth, Ayurcann Holdings Corp. faces substantial operational and financial challenges, including persistent net losses, negative cash flows, a shrinking equity base, and increased leverage, all of which pose significant risks to financial stability.

Income Statement

Ayurcann Holdings Corp. has shown significant revenue growth, from $611,829 in 2020 to $28,674,900 in the TTM (Trailing-Twelve-Months) 2024, indicating strong top-line expansion. However, the company has consistently reported negative net income, with a net profit margin of -12.18% in TTM 2024. The negative EBIT and EBITDA margins highlight ongoing operational inefficiencies and profitability challenges.

Balance Sheet

The debt-to-equity ratio has worsened as the equity base has significantly shrunk to $166,399 in TTM 2024 from $4,749,223 in 2021. This highlights a concerning increase in financial leverage. Additionally, the equity ratio has declined, indicating a higher reliance on debt financing, which could pose risks if the company's operational losses persist.

Cash Flow

The cash flow situation remains challenging, with a negative operating cash flow of -$1,029,359 in TTM 2024, indicating that the company is not generating sufficient cash from its operations. The free cash flow to net income ratio is negative, and free cash flow has continued to deteriorate, reflecting ongoing cash burn and potential liquidity concerns.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Sep 2020
Income Statement
Total Revenue	25.16M	12.49M	9.39M	7.63M	611.83K
Gross Profit	8.46M	3.68M	2.22M	4.63M	371.40K
EBITDA	-2.01M	-4.50M	-3.01M	653.98K	-245.00K
Net Income	-3.97M	-5.31M	-3.09M	-278.00K	-237.00K
Balance Sheet
Total Assets	14.85M	12.73M	7.28M	6.68M	1.13M
Cash, Cash Equivalents and Short-Term Investments	639.09K	971.96K	1.35M	725.02K	1.12M
Total Debt	894.64K	180.90K	356.08K	475.04K	484.31K
Total Liabilities	14.32M	10.04M	2.39M	1.93M	18.27K
Stockholders Equity	534.88K	2.69M	4.89M	4.75M	1.11M
Cash Flow
Free Cash Flow	-534.84K	-568.67K	-312.71K	-707.55K	-637.10K
Operating Cash Flow	-96.89K	-271.30K	-50.09K	-198.56K	-235.95K
Investing Cash Flow	-437.94K	-297.38K	-262.62K	363.25K	-401.15K
Financing Cash Flow	-48.03K	185.82K	942.51K	537.89K	245.24K

Ayurcann Holdings Corp. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AYUR, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.24 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AYUR.

Ayurcann Holdings Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DHB	64 Neutral	C$7.19M	181.82	-3.45%	―	4.04%	80.24%
XBRA	49 Neutral	C$1.50M	―	-542.08%	―	-100.00%	43.66%
AYUR	48 Neutral	C$4.87M	―	-271.33%	―	27.80%	31.16%
Sector *	46 Neutral	C$197.02M	-3.33	-23.14%	2.65%	20.75%	-0.36%
FFNT	39 Underperform	$4.58M	―	74.96%	―	-34.09%	71.95%
LOBE	38 Underperform	C$7.71M	―	141.95%	―	-100.00%	0.36%
AION	31 Underperform	C$2.42M	―		―	563.34%	-68.82%

Ayurcann Holdings Corp. Corporate Events

Ayurcann Holdings Corp. Reports Record Q3 2025 Growth and Expands Market Presence

Ayurcann Holdings Corp. reported record-breaking financial results for Q3 2025, with a gross revenue of $14,179,974, marking a 22% year-over-year increase. The company has achieved significant market share, being a top 3 vape producer in Ontario and holding a 5% national market share. With a focus on operational efficiency and a growing national footprint, Ayurcann is well-positioned for sustainable growth, despite industry challenges. The company is actively expanding its product categories and geographic reach to drive future revenue growth.